3-Hydroxymorphinan
Source: Wikipedia, the free encyclopedia.
Chemical compound
Clinical data | |
---|---|
ATC code |
|
Pharmacokinetic data | |
Bioavailability | 18% |
Identifiers | |
| |
JSmol) | |
| |
| |
NY (what is this?) (verify) |
3-Hydroxymorphinan (3-HM), or morphinan-3-ol, is a
racemic counterpart to norlevorphanol
.
The
presynaptic voltage-dependent Ca2+ entry and protein kinase C activity.[7] In any case, as such, the compound has been investigated as a potential management of Parkinson's disease medication (antiparkinsonian agent). A prodrug, GCC1290K, has been developed on account of 3-HM's poor bioavailability (18%), and a New Drug Application has been approved for it by the United States Food and Drug Administration.[6] It is currently undergoing clinical trials for the treatment of Parkinson's disease.[6] It does not have a Controlled Substances Act 1970 schedule, ACSCN, or annual aggregate manufacturing quota and may not necessarily be controlled, whilst norlevorphanol is; none of the dextrorotary derivatives of the dromoran and norlevorphanol sub-families of morphinan derivatives are controlled as they do not have opioid activity but the other racemic compounds are.[8]
3-HM's
analogue levorphanol.[10]
References
- ISBN 978-0-412-46630-4. Retrieved 29 November 2011.
- PMID 1306804.
- S2CID 13513164.
- S2CID 23032934.
- PMID 18198471.
- ^ PMID 21606622.
- S2CID 23428637.
- ^ "Conversion Factors for Controlled Substances". Diversion Control Division. Drug Enforcement Agency, U.S. Department of Justice. Archived from the original on 2016-03-02. Retrieved 2016-02-27.
- ISBN 0-412-54090-8.
- ^ Bentham Science Publishers (April 1995). Current Medicinal Chemistry. Bentham Science Publishers. p. 425. Retrieved 29 November 2011.
Dopaminergics |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Anticholinergics | |||||||||||
Others | |||||||||||
|
μ-opioid (MOR) |
| ||||
---|---|---|---|---|---|
δ-opioid (DOR) |
| ||||
κ-opioid (KOR) |
| ||||
Nociceptin (NOP) |
| ||||
Others |
|